Enfuvirtide: a new class of antiretroviral therapy for HIV infection
- 1 November 2004
- journal article
- Published by Wiley in Oral Diseases
- Vol. 10 (6) , 327-329
- https://doi.org/10.1111/j.1601-0825.2004.01042.x
Abstract
Enfuvirtide is the first of a new class of antiretroviral agents recently approved for the treatment of human immunodeficiency virus (HIV)-1 infection. Present available data suggest that enfuvirtide may be a promising agent for the control of HIV infection in patients who have previously received reverse transcriptase inhibitor and protease inhibitor regimens and who are either intolerant to such drugs and/or who have gone into virological failure. Perhaps the greater limitation to the clinical use of enfuvirtide is the cost, limiting its use in the developing world.Keywords
This publication has 22 references indexed in Scilit:
- Effects of Drug Resistance Mutations L100I and V106A on the Binding of Pyrrolobenzoxazepinone Nonnucleoside Inhibitors to the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Catalytic ComplexAntimicrobial Agents and Chemotherapy, 2004
- Differences in Durability of Treatment with Initial PI-Based RegimensHIV Research & Clinical Practice, 2003
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtideJournal of the American Academy of Dermatology, 2003
- Hypertension among HIV patientsJournal Of Hypertension, 2003
- Novel Therapies Based on Mechanisms of HIV-1 Cell EntryNew England Journal of Medicine, 2003
- US FDA approves new class of HIV therapeuticsNature Biotechnology, 2003
- Atherosclerosis and HIV in the highly active antiretroviral therapy eraAIDS, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily LivingAIDS Patient Care and STDs, 2002
- Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) MonotherapyAntimicrobial Agents and Chemotherapy, 2002